SEARCH

SEARCH BY CITATION

References

  • 1
    Samuel D, Muller R, Alexander G, et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993; 329: 1842.
  • 2
    Müller R, Samuel D, Fassati LR, Benhamou JP, Bismuth H, Alexander GJ. Eurohep consensus report on the management of liver transplantation for hepatitis B virus infection. J Hepatol 1994; 21: 1140.
  • 3
    Anselmo DM, Ghobrial RM, Jung LC, et al. New era of liver transplantation for hepatitis B. A 17-year single center experience. Ann Surg 2002; 235: 611.
  • 4
    Buti M, Mas A, Prieto M, et al. A randomized study comparing lamivudine monotherapy after a short course of hepatitis B immune globulin (HBIg) and lamivudine with long-term lamivudine plus HBIg in the prevention of hepatitis B virus recurrence after liver transplantation. J Hepatol 2003; 38: 811.
  • 5
    Han S-HB, Ofman J, Holt C, et al. An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy. Liver Transpl 2000; 6: 741.
  • 6
    Marzano A, Salizzoni M, Debernardi-Venon W, et al. Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis. J Hepatol 2001; 34: 903.
  • 7
    Nery JR, Weppler D, Rodriguez M, Riuz P, Schiff ER, Tzakis AG. Efficacy of lamivudine in controlling hepatitis B virus recurrence after liver transplantation. Transplantation 1998; 65: 1615.
  • 8
    Rosenau J, Bahr MJ, Tillmann HL, et al. Lamivudine and low-dose hepatitis B immune globulin for prophylaxis of hepatitis B reinfection after liver transplantation – possible role of mutations in the YMDD motif prior to transplantation as a risk factor for reinfection. J Hepatol 2001; 34: 895.
  • 9
    Steinmüller T, Seehofer D, Rayes N, et al. Increasing applicability of liver transplantation for patients with hepatitis B-related liver disease. Hepatology 2002; 35: 1528.
  • 10
    Yao FY, Osorio RW, Roberts JP, et al. Intramuscular hepatitis B immune globulin combined with lamivudine for prophylaxis against hepatitis B recurrence after liver transplantation. Liver Transpl Surg 1999; 5: 491.
  • 11
    Tipples GA, Ma MM, Fischer KP, Bain VG, Kneteman NM, Tyrrell DLJ. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 1996; 24: 714.
  • 12
    Ben-Ari Z, Pappo O, Zemel R, Mor E, Tur-Kaspa R. Association of lamivudine resistance in recurrent hepatitis B after liver transplantation with advanced hepatic fibrosis. Transplantation 1999; 68: 232.
  • 13
    Chan HL, Chui AK, Lau WY, et al. Factors associated with viral breakthrough in lamivudine monoprophylaxis of hepatitis B virus recurrence after liver transplantation. J Med Virol 2002; 68: 182.
  • 14
    Mutimer D, Pillay D, Shields P, et al. Outcome of lamivudine resistant hepatitis B virus infection in the liver transplant recipient. Gut 2000; 46: 107.
  • 15
    Fontana RJ, Hann H-WL, Wright T, et al. A multicenter study of lamivudine treatment in 33 patients with hepatitis B after liver transplantation. Liver Transpl 2001; 7: 504.
  • 16
    Perrillo RP, Wright T, Rakela J, et al. A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology 2001; 33: 424.
  • 17
    Bartholomew MM, Jansen RW, Jeffers LJ, et al. Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 1997; 349: 20.
  • 18
    Perrillo RP, Rakela J, Dienstag J, et al. Multicenter study of lamivudine therapy for hepatitis B after liver transplantation. Hepatology 1999; 29: 1581.
  • 19
    Ben-Ari Z, Mor E, Tur-Kaspa R. Experience with lamivudine therapy for hepatitis B virus infection before and after liver transplantation, and review of the literature. J Int Med 2003; 253: 544.
  • 20
    Tillmann HL, Rosenau J, Trautwein C, Boeker KH, Manns MP. Successful orthotopic liver transplantation. Gastroenterology 2001; 120: 1561.
  • 21
    Samuel D. Liver transplantation and hepatitis B virus infection: the situation seems to be under control, but the virus is still there. J Hepatol 2001; 34: 943.
  • 22
    Hadziyannis SJ, Papatheodoridis GV, Dimou E, Laras A, Papaioannou C. Efficacy of long-term lamivudine monotherapy in patients with hepatitis Be antigen-negative chronic hepatitis B. Hepatology 2000; 32: 847.
  • 23
    Mutimer D, Pillay D, Dragon E, et al. High pre-treatment serum hepatitis B virus titre predicts failure of lamivudine prophylaxis and graft re-infection after liver transplantation. J Hepatol 1999; 30: 715.
  • 24
    Naoumov NV, Lopes AR, Burra P, et al. Randomized trial of lamivudine versus hepatitis B immunoglobulin for long-term prophylaxis against hepatitis B recurrence after liver transplantation. J Hepatol 2001; 34: 888.
  • 25
    Hunt C, McGill JM, Allen MI, Condreay LD. Clinical relevance of hepatitis B virus mutations. Hepatology 2000; 31: 1037.
  • 26
    Mutimer D, Dusheiko G, Barret C, et al. Lamivudine without HBIg for prevention of graft reinfection by hepatitis B: long-term follow-up. Transplantation 2000; 70: 809.
  • 27
    Caccamo L, Rossi G, Reggiani P, et al. Liver transplantation for viral hepatitis-associated cirrhosis. Transplant Proc 1998; 30: 2107.
  • 28
    Dodson SF, de Vera ME, Bonham CA, Geller DA, Rakela J, Fung JJ. Lamivudine after hepatitis B immune globulin is effective in preventing hepatitis B recurrence after liver transplantation. Liver Transplant 2000; 6: 434.